Significant interaction between testosterone recovery (TR) and biochemical progression-free survival (BPFS) in intermediate- and high-risk patients with prostate cancer treated with radiation therapy (RT) and androgen deprivation therapy (ADT).

202 Background: To examine the interaction testosterone-recovery-free survival (TRFS) and BPFS in patients with intermediate and high-risk prostate cancer treated with combined external beam radiation therapy (EBRT), prostate implant (PI), and ADT. Methods: We prospectively collected data between 1998 and 2010 from 1,564 patients with clinically localized prostate cancer treated by a single physician (DS). 294 patients with NCCN intermediate or high-risk prostate cancer were treated with EBRT, PI, and ADT. 60% of these patients had intermediate-risk disease. Initial prostate-specifc antigen (PSA), Gleason Score (GS), AJCC tumor stage (TStage), and RT parameters were recorded. PSA, and testosterone (T) were measured at each follow-up visit. BPFS was scored using the Phoenix definition. Testosterone recovery occurred when the serum T level rose above 150ng/ml. TR was dichotomized at 2 years. Survival was evaluated using Cox-regression analysis. Results: Median age was 66 yrs-old, intraquartile range (IQR) w...